<DOC>
	<DOCNO>NCT02280694</DOCNO>
	<brief_summary>This study investigate activity new regimen treatment patient metastatic colorectal carcinoma . This include combination well-known chemotherapy agent anti-inflammatory agent , administer orally low daily dos without plan brake ( Low Dose Metronomic regimen ) , contrast conventional already exhaust regimen treatment Maximal Tolerated Doses ( MTD ) require pre-planned brake treatment day .</brief_summary>
	<brief_title>Low Dose Metronomic Poly-chemotherapy Metastatic CRC</brief_title>
	<detailed_description>Patients suffer metastasis colorectal cancer whose tumor cell develop resistance conventionally administer treatment need new method treatment . While chemotherapy administer till classical regimen Maximal Tolerated Doses ( MTD ) , aim directly kill maximal fraction tumor cell , present study evaluate clinical benefit treatment base old chemotherapeutic old anti-inflammatory drug , administer low dos , daily basis orally take , without plan brake ( Low Dose Metronomic regimen ) . Treatments base type regimen already study model cancer show capacity suppress tumor growth new category anti-tumor effect . Namely , affect factor mechanisms prevail microenvironment surround tumor deposit , thus circumvent resistance cancer cell chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Histological ( cytological ) proof colorectal carcinoma ( CRC ) 2 . Measurable metastasis 3 . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 4 . Progressing disease follow available chemotherapy treatment line ( include chemotherapy , bevacizumab+/zivaflibercept , epidermal growth factor receptor ( EGFR ) inhibitor [ WT ( wild type ) KRAS ] 5 . The centralradiologist 's confirmation PD* last ( previous ) line `` conventional treatment '' . * PD ( progressive disease ) RECIST ( Response Evaluation Criteria Solid Tumors ) criterion : ) 20 % relative increment sum diameter target lesion comparison base line sum , absolute increase 5 mm . , b ) appear one new lesion , c ) substantial worsen nontarget disease 6 . Age : 18 85 7 . Prior radiotherapy either adjuvant treatment palliation allow , unless deliver measurable lesion 8 . Complete blood count reflect adequate Bone Marrow : Hb=/ &gt; 9 g/dL , ANC=/ &gt; 1,500 Plt =/ &gt; 75,000/mcL ; 9 . Adequate liver function : 1 . Total Bilirubin always =/ &lt; X1.5 ULN 2 . ALT AST Alkaline Phosphatase =/ &lt; 2.5 X upper normal limit , although patient liver metastasis acceptable =/ &lt; 5 X ULN ; 11 . Adequate renal function ( serum creatinine ) : =/ &lt; 1.5 X ULN . 12 . Absence nonhematological toxicity grade 2 high . 13.The patient able understand ready sign inform consent 1 . Lack confirmation PD ( prestudy treatment ) central radiologist 2 . Any concurrent active cancer ( except basal cell squamous cell carcinoma skin early prostate cancer DCIS situ breast cancer ) 3 . Inability adhere monthly visit oncological unit evaluation 4 . Presence brain metastases 5 . Continuous treatment steroid NSAIDs anticoagulant last year ( except micropirin ) 6 . Previous radiotherapy site measurable disease 7 . Existence active peptic ulcer symptomatic coronary disease 8 . Existence chronic inflammatory disease , ulcerative colitis Crohn 's disease rheumatoid arthritis 9 . Presence ascites , and/or `` third space '' finding ( eg . significant leg edema )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>